Sequential, Two-period Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Patients With FXS (Fragile X Syndrome) Aged 5-11 Years (Cohort 1) and 3-4 Years (Cohort 2)
Phase of Trial: Phase I
Latest Information Update: 11 Nov 2014
At a glance
- Drugs Mavoglurant (Primary)
- Indications Fragile X syndrome
- Focus Pharmacokinetics
- Sponsors Novartis
- 20 Nov 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Oct 2013 Planned end date changed from 1 Jun 2014 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 14 Mar 2013 Planned End Date changed from 1 Aug 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.